A very important study for advanced, locally advanced cases is nearing it's tenth year.
This study RTOG 94-13 has already acheived great results with patients that have exceeded 10 years. Below is the study guidelines:
RTOG 94-13 (PROSTATE)
- Title: A Phase III Trial Comparing Whole Pelvic Irradiation Followed by a Conedown Boost to Boost Irradiation Only and Comparing Neoadjuvant to Adjuvant Total Androgen Suppression (TAS)
- Objectives:
- (1) To test the hypothesis that TAS and whole pelvic irradiation followed by a conedown boost to the prostate improves the progression-free survival (an "early endpoint") by at least 10% at 5 years compared to TAS and prostate only irradiation.
- (2) To test the hypothesis that induction (neoadjuvant) and concurrent TAS and RT, improves the progression-free survival (an "early endpoint") compared to adjuvant TAS and RT by at least 10% at 5 years. (10/13/95)
- Protocol:
- Arm 1: Neoadjuvant TAS 2 months before and during RT to the whole pelvis + prostate boost (70.2 Gy)
- Arm 2: Neoadjuvant TAS 2 months before and during 70.2 Gy RT to prostate only (70.2 Gy)
- Arm 3: RT to the whole pelvis + prostate boost (70.2 Gy) followed by 4 months of TAS
- Arm 4: RT to the prostate only (70.2 Gy) followed by 4 months of TAS
- Eligibility: Risk of LN involvement >15% based on pretreatment PSA and GS, N0M0; must not be eligible for RTOG 94-08
- Enroll Target: 1200 patients
- Activation: April 1, 1995
- Closed: June 1, 1999
Related Information:
RTOG ~ Radiation Therapy Oncology Group... www.rtog.org
http://jco.ascopubs.org/cgi/content/full/21/10/1899 (Thanks Goody5)
Important note:
Stanford University enhanced this study by addressing post prostatectomy treatment including ADT and WPRT. The criteria at Stanford was PSA >20, High Risk disease (Gleason 7>, and stage III). The stanford results after five years showed more than twice as many patients in remission at year five. The Stanford study is significant because IMRT was used. RTOG was started and completed before IMRT. IMRT allows higher concentration dosing in smaller areas. There is no certanty that IGRT or Proton will share the same results results. I'd like to see that result, but we'll have to wait quite some time.
http://med.stanford.edu/profiles/radonc/frdActionServlet?choiceId=showPublication&pubid=237606&fid=4626
http://www.ncbi.nlm.nih.gov/pubmed/17459606?dopt=Abstract&otool=stanford
Post Edited (TC-LasVegas) : 4/12/2008 7:01:54 PM (GMT-6)